EMERGENT BIOSOLUTIONS INC (EBS)       13.47  +0.35 (+2.67%)

13.47  +0.35 (+2.67%)

US29089Q1058 - Common Stock - After market: 14.15 +0.68 (+5.05%)

News Image
11 days ago - MarketBeat

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.

News Image
24 days ago - Seeking Alpha

Emergent BioSolutions (NYSE:EBS) gets ~$380M military contract

Emergent BioSolutions (EBS) has been awarded a contract valued up to ~$380M to supply skin decontamination lotion kits for use by all branches of the U.S. military. Read more here.

News Image
24 days ago - Emergent BioSolutions

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery,...

News Image
2 months ago - Market News Video

Emergent BioSolutions is Now Oversold (EBS)

News Image
2 months ago - Emergent BioSolutions

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

Emergent’s supplemental new drug application is the first prescription-to-over-the-counter switch application in history to be granted Priority Review by...

News Image
3 months ago - Emergent BioSolutions

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies...

News Image
3 months ago - Emergent BioSolutions

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies

News Image
3 months ago - Market News Video

Emergent BioSolutions is Now Oversold (EBS)

News Image
3 months ago - Investor's Business Daily

Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing

Biotech stocks were hammered Wednesday, including several that had good news.

News Image
3 months ago - The Motley Fool

Emergent BioSolutions (EBS) Q3 2022 Earnings Call Transcript

EBS earnings call for the period ending September 30, 2022.

News Image
3 months ago - Emergent BioSolutions

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

GAITHERSBURG, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended...

News Image
3 months ago - Emergent BioSolutions

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety...

News Image
3 months ago - InvestorPlace

Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst

Although blue chips provide greater predictability, these top small-cap stocks to buy may drive intense growth for speculators.

News Image
3 months ago - Emergent BioSolutions

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at...

News Image
4 months ago - Emergent BioSolutions

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of...

News Image
5 months ago - Emergent BioSolutions

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in...

News Image
5 months ago - InvestorPlace

3 Top Monkeypox Stocks to Buy Right Now

With cases of a frightening disease spreading to all 50 states, it’s now time to consider the top monkeypox stocks to buy right now.